Haptoglobin Genotype Is Predictive of Major Adverse Cardiac Events in the 1-year Period after Percutaneous Transluminal Coronary Angioplasty in Individuals with Diabetes

OBJECTIVE The goal of this study was to determine whether the haptoglobin (Hp) genotype was predictive of restenosis and major adverse cardiac events (MACEs) after percutaneous transluminal coronary angioplasty (PTCA) in individuals with diabetes. RESEARCH DESIGN AND METHODS A consecutive series of 935 diabetic patients treated with oral agents and/or insulin were followed for 1 year after PTCA. The primary study end point was angiographic restenosis, MACEs and secondary study end points were defined as target vessel revascularization, myocardial infarction, and death. Two alleles exist at the Hp gene locus, denoted 1 and 2. The Hp genotype (Hp 1-1, Hp 2-1, or Hp 2-2) was determined by PCR. RESULTS In multivariate analysis controlling for all known determinants of outcome after PTCA, we found that the Hp genotype was a highly significant independent predictor of MACEs in the 1-year period after PTCA in individuals with diabetes. This was predominantly due to differences in the risk of myocardial infarction during that period: Hp 1-1, 0 of 129 (0%); Hp 2-1, 20 of 424 (4.7%); and Hp 2-2, 32 of 382 (8.4%); P < 0.0001. CONCLUSIONS The Hp genotype seems to be highly predictive of adverse cardiac events, particularly myocardial infarction, in the 1-year period after PTCA. Determination of the Hp genotype may be useful in the evaluation of new therapies to reduce cardiovascular risk after PTCA.

[1]  A. Roguin,et al.  Haptoglobin type and 30-day mortality in diabetic individuals presenting with acute myocardial infarction. , 2003, Diabetes care.

[2]  A. Levy,et al.  Genetically Determined Heterogeneity in Hemoglobin Scavenging and Susceptibility to Diabetic Cardiovascular Disease , 2003, Circulation research.

[3]  K. Jablonski,et al.  Haptoglobin phenotype is an independent risk factor for cardiovascular disease in individuals with diabetes: The Strong Heart Study. , 2002, Journal of the American College of Cardiology.

[4]  A. Kastrati,et al.  Genotyping of the common haptoglobin Hp 1/2 polymorphism based on PCR. , 2002, Clinical chemistry.

[5]  I. Hochberg,et al.  Haptoglobin phenotype and coronary artery collaterals in diabetic patients. , 2002, Atherosclerosis.

[6]  G. Matullo,et al.  Haptoglobin phenotype and the risk of restenosis after coronary artery stent implantation. , 2002, The American journal of cardiology.

[7]  B V Howard,et al.  Diabetes and cardiovascular disease. , 2002, Annual review of medicine.

[8]  A. Levy,et al.  Structure-function analysis of the antioxidant properties of haptoglobin. , 2001, Blood.

[9]  I. Hochberg,et al.  Haptoglobin phenotype and diabetic nephropathy , 2001, Diabetologia.

[10]  I. Hochberg,et al.  Haptoglobin phenotype as a predictor of restenosis after percutaneous transluminal coronary angioplasty. , 2001, The American journal of cardiology.

[11]  I. Hochberg,et al.  Haptoglobin phenotype and vascular complications in patients with diabetes. , 2000, The New England journal of medicine.

[12]  I. Hochberg,et al.  Haptoglobin genotype as a risk factor for diabetic retinopathy. , 2000, JAMA.

[13]  P. Ruszniewski,et al.  Ulcerative colitis in a sigmoid neovagina. , 2000, The New England journal of medicine.

[14]  A. Kastrati,et al.  Insertion/deletion polymorphism of the angiotensin I-converting enzyme gene is not associated with restenosis after coronary stent placement. , 2000, Circulation.

[15]  A. Kastrati,et al.  Polymorphism of platelet glycoprotein IIb and risk of thrombosis and restenosis after coronary stent placement. , 1999, The American journal of cardiology.

[16]  B. Howard,et al.  Rising tide of cardiovascular disease in American Indians. The Strong Heart Study. , 1999, Circulation.

[17]  A. Kastrati,et al.  PlA polymorphism of platelet glycoprotein IIIa and risk of restenosis after coronary stent placement. , 1999, Circulation.

[18]  R. Kuntz.  Importance of considering atherosclerosis progression when choosing a coronary revascularization strategy: the diabetes-percutaneous transluminal coronary angioplasty dilemma. , 1999, Circulation.

[19]  R. Califf,et al.  Coronary revascularization in diabetic patients: a comparison of the randomized and observational components of the Aypass Angioplasty Revascularization Investigation (BARI). , 1999, Circulation.

[20]  Ethnicity and Cardiovascular Disease: The incidence of myocardial infarction in white, South Asian, and Afro-Caribbean patients with type 2 diabetes (U.K. Prospective Diabetes Study 32) , 1998, Diabetes Care.

[21]  R. Califf,et al.  Relationship between diabetes mellitus and long-term survival after coronary bypass and angioplasty. , 1997, Circulation.

[22]  T. B. Investigators,et al.  Influence of diabetes on 5-year mortality and morbidity in a randomized trial comparing CABG and PTCA in patients with multivessel disease: the Bypass Angioplasty Revascularization Investigation (BARI) , 1997, Circulation.

[23]  J. Herlitz,et al.  Mortality and Morbidity in Diabetic and Nondiabetic Patients During a 2-Year Period After Coronary Artery Bypass Grafting , 1996, Diabetes Care.

[24]  W. Weintraub,et al.  Influence of diabetes mellitus on early and late outcome after percutaneous transluminal coronary angioplasty. , 1995, Circulation.

[25]  G. Vetrovec,et al.  Coronary collateral recruitment: functional significance and relation to rate of vessel closure. , 1991, American heart journal.

[26]  E. Jones,et al.  Outcome of coronary bypass surgery versus coronary angioplasty in diabetic patients with multivessel coronary artery disease. , 1998, Journal of the American College of Cardiology.

[27]  J. Willerson.  Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. , 1996, Circulation.

[28]  A. Kurosky,et al.  Haptoglobin: the evolutionary product of duplication, unequal crossing over, and point mutation. , 1982, Advances in human genetics.